A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern

References

• Mahase E. Covid-19: Pfizer vaccine’s efficacy declined from 96% to 84% four months after second dose, company reports. BMJ. 2021 Jul 30;374:n1920.
   PubMedGoogle Scholar
• Shrotri M, Navaratnam AMD, Nguyen V, et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021 Jul 31;398(10298):385–387.
   PubMed Web of Science ®Google Scholar
• McDade TW, Demonbreun AR, Sancilio A, et al. Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history. Sci Rep. 2021 Aug 30;11(1):17325.
   PubMed Web of Science ®Google Scholar
• Pollet J, Chen WH, Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev. 2021 Mar;170:71–82.
   PubMed Web of Science ®Google Scholar
• Barnes CO, West AP, Jr., Huey-Tubman KE, et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell. 2020 Aug 20;182(4):828-842 e16.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584(7821):450–456.
   PubMed Web of Science ®Google Scholar
• Brouwer PJM, Caniels TG, van der Straten K, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369(6504):643–650.
   PubMed Web of Science ®Google Scholar
• Piccoli L, Park YJ, Tortorici MA, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020 Nov 12;183(4):1024–1042 e21.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang W, Chen Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;586(7830):572–577.
   PubMed Web of Science ®Google Scholar
• Srivastava V, Niu L, Phadke KS, et al. Induction of potent and durable neutralizing antibodies against SARS-CoV-2 using a receptor binding domain-based immunogen. Front Immunol. 2021;12:637982.
   PubMed Web of Science ®Google Scholar
• Kang YF, Sun C, Zhuang Z, et al. Rapid development of SARS-CoV-2 spike protein receptor-binding domain self-assembled nanoparticle vaccine candidates. ACS Nano. 2021;15(2):2738–2752.
   PubMed Web of Science ®Google Scholar
• Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. The Lancet Infectious Diseases. 2021 Aug;21(8):1107–1119.
   PubMed Web of Science ®Google Scholar
• Tan HX, Juno JA, Lee WS, et al. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nat Commun. 2021 Mar 3;12(1):1403.
   PubMed Web of Science ®Google Scholar
• Sun S, Cai Y, Song TZ, et al. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Res. 2021 Jul 15;31(9):1011–1023.
   PubMed Web of Science ®Google Scholar
• Zaharoff DA, Rogers CJ, Hance KW, et al. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine. 2007 Mar 1;25(11):2085–94.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Okada N, Oda A, et al. Development of amphiphilic gamma-PGA-nanoparticle based tumor vaccine: potential of the nanoparticulate cytosolic protein delivery carrier. Biochem Biophys Res Commun. 2008 Feb 8;366(2):408–13.
   PubMed Web of Science ®Google Scholar
• Liu YW, Chen YH, Chen JW, et al. Immunization with recombinant TcdB-encapsulated nanocomplex induces protection against clostridium difficile challenge in a mouse model. Front Microbiol. 2017;8:1411.
   PubMed Web of Science ®Google Scholar
• Wu YW, Chen MC, Chen YH. Potential Zika vaccine: encapsulated nanocomplex promotes both TH 1/TH 2 responses in mice. Advanced Therapeutics. 2020;3(3):1900197.
   Google Scholar
• Sun CP, Jan JT, Wang IH, et al. Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19. PLoS Pathog. 2021 Aug;17(8):e1009758.
   PubMed Web of Science ®Google Scholar
• Jiang RD, Liu MQ, Chen Y, et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell. 2020 Jul 9;182(1):50–58 e8.
   PubMed Web of Science ®Google Scholar
• Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019 Feb 21;4(4):e123158.
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003 Nov 27;426(6965):450–4.
   PubMed Web of Science ®Google Scholar
• Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–4.
   PubMed Web of Science ®Google Scholar
• Shah RR, Hassett KJ, Brito LA. Methods in molecular biology. Methods Mol Biol. 2017;1494:1–13.
   PubMedGoogle Scholar
• Iwasaki A, Omer SB. Why and How vaccines work. Cell. 2020 Oct 15;183(2):290–295.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Edwards JE, Jr. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis. 2001 Jan;32(1):76–102.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhou X, Zhu C, et al. Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients With COVID-19. Front Mol Biosci. 2020;7:157.
   PubMed Web of Science ®Google Scholar
• Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020 Jul;81(1):e6–e12.
   Web of Science ®Google Scholar
• Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812–827 e19.
   PubMed Web of Science ®Google Scholar
• Subbarao K. The success of SARS-CoV-2 vaccines and challenges ahead. Cell Host Microbe. 2021 Jul 14;29(7):1111–1123.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N Engl J Med. 2020 Dec 10;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Tanne JH. COVID-19: FDA panel votes to approve Pfizer BioNTech vaccine. BMJ. 2020 Dec 11;371:m4799.
   PubMedGoogle Scholar
• Lloyd J, Cheyne J. The origins of the vaccine cold chain and a glimpse of the future. Vaccine. 2017 Apr 19;35(17):2115–2120.
   PubMed Web of Science ®Google Scholar
• Stephenson KE, Le Gars M, Sadoff J, et al. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021 Mar 11;325(15):1535–1544.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99–111.
   PubMed Web of Science ®Google Scholar
• Tian JH, Patel N, Haupt R, et al. Single-molecule imaging with cell-derived nanovesicles reveals early binding dynamics at a cyclic nucleotide-gated ion channel. Nat Commun. 2021 Jan 14;12(1):372.
   PubMed Web of Science ®Google Scholar
• Bangaru S, Ozorowski G, Turner HL, et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science. 2020;370(6520):1089–1094.
   PubMed Web of Science ®Google Scholar
• Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine. N Engl J Med. 2021 Sep 23;385(13):1172–1183.
   PubMed Web of Science ®Google Scholar
• Ma X, Zou F, Yu F, et al. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity. 2020 Dec 15;53(6):1315–1330 e9.
   PubMed Web of Science ®Google Scholar
• Li H, Guo L, Zheng H, et al. Self-Assembling nanoparticle vaccines displaying the receptor binding domain of SARS-CoV-2 elicit robust protective immune responses in rhesus monkeys. Bioconjug Chem. 2021 May 5;32(5):1034–1046.
   PubMed Web of Science ®Google Scholar
• King HAD, Joyce MG, Lakhal-Naouar I, et al. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):e2106433118.
   PubMed Web of Science ®Google Scholar
• Walls AC, Fiala B, Schafer A, et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell. 2020 Nov 25;183(5):1367–1382 e17.
   PubMed Web of Science ®Google Scholar
• Arunachalam PS, Walls AC, Golden N, et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature. 2021 Jun;594(7862):253–258.
   PubMed Web of Science ®Google Scholar
• Fougeroux C, Goksoyr L, Idorn M, et al. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nat Commun. 2021 Jan 12;12(1):324.
   PubMed Web of Science ®Google Scholar
• Tan TK, Rijal P, Rahikainen R, et al. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nat Commun. 2021 Jan 22;12(1):542.
   PubMed Web of Science ®Google Scholar
• Pan J, Cui Z. Self-assembled nanoparticles: exciting platforms for vaccination. Biotechnol J. 2020 Dec;15(12):e2000087.
   PubMed Web of Science ®Google Scholar
• Volz E, Hill V, McCrone JT, et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell. 2021;184(1):64–75 e11.
   PubMed Web of Science ®Google Scholar
• Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021 Apr 9;372(6538):eabg3055.
   PubMed Web of Science ®Google Scholar
• Davies NG, Jarvis CI, Group CC-W, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;593(7858):270–274.
   PubMed Web of Science ®Google Scholar
• Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021 Apr;592(7854):438–443.
   PubMed Web of Science ®Google Scholar
• Pegu A, O'Connell S, Schmidt SD, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021;373(6561):1372–1377.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Arora P, Gross R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184(9):2384–2393 e12.
   PubMed Web of Science ®Google Scholar
• Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021 Mar 26;27(5):917–924.
   PubMed Web of Science ®Google Scholar
• Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184(9):2348–2361 e6.
   PubMed Web of Science ®Google Scholar
• Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021 Jun 19;397(10292):2331–2333.
   PubMed Web of Science ®Google Scholar
• Slifka MK, Amanna IJ. Role of multivalency and antigenic threshold in generating protective antibody responses. Front Immunol. 2019;10:956.
   PubMed Web of Science ®Google Scholar